Elsevier Inc.

SHERPA: Unknown

People

  1. Mauro
    Mauro
  2. Perales
    Perales
  3. Park
    Park
  4. Giralt
    Giralt
  5. Rampal
    Rampal
  6. Scheinberg
    Scheinberg
  7. Levine
    Levine
  8. Stein
    Stein
  9. Tallman
    Tallman
  10. Palomba
    Palomba

Groups

  1. Adult Leukemia (256)
  2. Center for Hematologic Malignancies (256)
  3. Department of Medicine (253)
  4. Hematologic Malignancies, Division of (252)
  5. GSK Faculty (83)
  6. Hematologic Malignancies Research (49)
  7. Tow Center for Developmental Oncology (TCDO) (45)
  8. Sloan Kettering Institute Faculty (43)
  9. Center for Molecular Imaging and Biotechnology (41)
  10. Bone Marrow Transplant (39)
Search Within
  1. "Adult Leukemia"
Formats
  1. Meeting Abstract (136)
  2. Journal Article (95)
  3. Review (17)
  4. Editorial (3)
  5. Book Section (2)
  6. Guidelines (2)
  7. Conference Paper (1)
Groups
  1. Adult Leukemia (256)
  2. Center for Hematologic Malignancies (256)
  3. Department of Medicine (253)
  4. Hematologic Malignancies, Division of (252)
  5. GSK Faculty (83)
  6. Hematologic Malignancies Research (49)

More Groups

People
  1. Michael Mauro (47)
  2. Martin Tallman (43)
  3. Jae Park (34)
  4. Eytan Stein (30)
  5. Miguel-Angel Perales (28)
  6. Renier Brentjens (25)

More People

Years
  1. 2025 (3)
  2. 2024 (7)
  3. 2023 (12)
  4. 2022 (32)
  5. 2021 (29)
  6. 2020 (24)

More Years

Publications
  1. Clinical Lymphoma, Myeloma and Leukemia (116)
  2. Biology of Blood and Marrow Transplantation (39)
  3. Transplantation and Cellular Therapy (15)
  4. Hematology/Oncology Clinics of North America (14)
  5. Best Practice and Research: Clinical Haematology (13)
  6. European Journal of Cancer (7)

More Publications

Results (256)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Risk factors associated with sub-optimal outcomes and hematotoxicity following obecabtagene autoleucel (obe-cel) for relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL)
    Meeting Abstract

    Sandhu, K. S.; Park, J. H.; Shaughnessy, P.; Logan, A. C.; Abedi, M.; Shah, B.; Bishop, M. R.; Deangelo, D. J.; Brugger, W.; Shang, J.; more...
    Transplantation and Cellular Therapy (2025)

    Fulltext@MSK | Save
  • Enhancing the persistence and anti-tumor efficacy of CAR-T and CAR-NK cells through genetic disruption of death receptors
    Meeting Abstract

    Cohen, T. D.; Yi, F.; Zumbo, P.; Etilib, R.; Arkin, H.; Gormally, M.; Hackett, C. S.; Kropp, K.; Etxeberria, I.; Chandran, S. S.; more...
    Transplantation and Cellular Therapy (2025)

    Fulltext@MSK | Save
  • Shift from widespread to tailored antifungal prophylaxis in lymphoma patients treated with CD19 CAR T cell therapy: Results from a large retrospective cohort
    Journal Article

    Melica, G.; Luna de Abia, A.; Shah, G. L.; Devlin, S.; Corona, M.; Fein, J.; Dahi, P. B.; Giralt, S. A.; Lin, R. J.; Palomba, M. L.; more...
    Transplantation and Cellular Therapy (2025)

    Fulltext@MSK | Save
  • A proof-of-principle study of split-course bridging radiotherapy (SC-BRT) prior to commercial CAR T-cell therapies for relapsed or refractory B-cell lymphomas: Results from phase 1a pilot cohort
    Meeting Abstract

    Imber, B. S.; Palomba, M. L.; Brosoff, A.; Roszak, E.; McAvoy, D.; Hosszu, K.; Boardman, A.; Dahi, P. B.; Lin, R. J.; Shah, G. L.; more...
    International Journal of Radiation Oncology, Biology, Physics (2024)

    Fulltext@MSK | Save
  • Improvement in radiomic features following bridging therapy is prognostic for CD19 chimeric antigen receptor (CAR) T-cell therapy outcome
    Meeting Abstract

    Hubbeling, H. G.; Leithner, D.; Silverman, E. A.; Flynn, J.; Devlin, S.; Shah, G. L.; Fregonese, B.; Bedmutha, A.; Boardman, A.; Dahi, P. B.; more...
    International Journal of Radiation Oncology, Biology, Physics (2024)

    Fulltext@MSK | Save
  • Pelabresib plus ruxolitinib combination therapy in jak inhibitor-naïve patients with myelofibrosis in the phase 3 MANIFEST-2 study: Preliminary evidence of bone marrow recovery
    Meeting Abstract

    Mascarenhas, J.; Rampal, R. K.; Vannucchi, A. M.; Gupta, V.; Oh, S. T.; Kuykendall, A. T.; Mesa, R.; Kiladjian, J. J.; Talpaz, M.; Kremyanskaya, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Dose-optimization study of 3 starting doses of ponatinib: Long-term results from the OPTIC trial
    Meeting Abstract

    Cortes, J.; Deininger, M.; Lomaia, E.; Moiraghi, B.; Sutton, M. U.; Pavlovsky, C.; Chuah, C.; Sacha, T.; Lipton, J. H.; McCloskey, J.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • A phase 1 trial of valemetostat in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) or acute lymphocytic leukemia (ALL)
    Meeting Abstract

    Erba, H. P.; Oluwole, O. O.; Bixby, D.; Rampal, R. K.; Fathi, A. T.; Paliwal, P.; Jin, J.; Inoue, A.; Daver, N.
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Cautionary tale of unopposed prophylactic il6 receptor blockade in axicabtagene ciloleucel for large B-cell lymphoma
    Editorial

    Valtis, Y. K.; Park, J. H.
    Transplantation and Cellular Therapy (2024)

    Fulltext@MSK | Save
  • Subsequent malignancies after CD19-targeted chimeric antigen receptor T cells in patients with lymphoma
    Journal Article

    Lorenc, R.; Shouval, R.; Flynn, J. R.; Devlin, S. M.; Saldia, A.; Luna De Abia, A.; De Lapuerta, M. C.; Tomas, A. A.; Cassanello, G.; Leslie, L. A.; more...
    Transplantation and Cellular Therapy (2024)

    Fulltext@MSK | Save